The national laboratory Novocap is tying its boots to go out into the field with a cutting-edge and differentiated technology in the local market.

English Version

The national laboratory Novocap is tying its boots to go out into the field with a cutting-edge and differentiated technology in the local market.

It is its new liquid-filled capsules, which were baptized LiquidCap in Argentina.

They are hard capsules with liquid or semi-solid filling that will be manufactured in its plant located in Avellaneda district. They are similar to the popular soft capsules that are very widespread in the OTC environment.

However, during a tour around Novocap’s local plant, Pharmabiz was told that the company will focus on providing this innovation not only for companies that produce OTC drugs but also for those which manufacture prescription drugs. 

According to officials of the firm, “this technology enables the development of products with clear pharmacotechnical and therapeutic benefits.”

Novocap will be the only company delivering this dosage form in Argentina. It is also going to make a big difference in Latin America.

Novocap ensures that the innovative LiquidCap have higher speed of action because «the active ingredient is dissolved and this allows rapid absorption.”

Additionally, the LiquidCap technology enables the development of capsules with faster disintegration time than soft capsules.

For this reason, this product could be interesting for Development divisions.

Meanwhile, there is a key piece of information for marketing teams: the product can be fully customized. That is to say, the color or color combination of the capsules can be chosen and it is even possible to imprint a logo on them.

In short, in an age where innovation in the pharmaceutical field is more related to the development of new dosage forms than to the emergence of new molecules, Novocap has found a good niche.

In the future, Novocap also aims to apply for the approval of the regulatory authorities in order to produce dietary supplements as well.

Artículo anteriorIndependiente a la B ¿Ibupirac desciende?
Artículo siguienteLiquidCap: nuevas cápsulas con líquido

DEJA UNA RESPUESTA

Escriba su comentario
Ingrese su nombre